

25 June 2018

OBJ Appoints Experienced Biotech Executive Cameron Reynolds to the Board

OBJ Limited (ASX: OBJ) is pleased to announce the appointment of experienced biotech executive Cameron Reynolds as a Non-Executive Director, effective 1 July 2018.

Mr Reynolds is currently the President, CEO and Director of VolitionRX, a biotech company which listed on the New York Stock Exchange in February 2015 after being founded by Mr Reynolds in 2010. He has built the company to now comprise a team of more than 40 employees across three continents.

He has extensive experience in the management, structuring, and strategic planning of start-up companies and in the course of his career has held positions including CEO, CFO and Non-Executive Director spanning various sectors in both public and private enterprises.

OBJ Interim Chairman Steven Schapera said the Board believed Mr Reynolds' extensive experience in management, structuring and strategic planning for companies, along with 25 years of entrepreneurial executive experience, would be valuable to OBJ.

"We are pleased to welcome Cameron to the Board, further strengthening our leadership of OBJ," he said.

"We are satisfied with our pursuit and appointment of new board members over the last 12 months and believe it positions OBJ well moving forward."

About OBJ

OBJ develops proprietary magnetic microarray drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies

OBJ has developed a number of physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces. These influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Directors

Mr Steven Schapera
Mr Jeffrey Edwards
Dr Chris Quirk
Mr Tony Varano

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011

www.obj.com.au
ABN: 72 056 482 636

25 June 2018

Complex 3-D magnetic fields produced by low cost microarrays or powered electromagnetic inductors have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of biological and non-biological targets.

OBJ's low-cost microarray film technology that utilises diamagnetic repulsion, induced permeation and energy redirection has already reached international markets to provide OBJ's Partners with a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical, healthcare and consumer products.

Forward-Looking Statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

Directors

Mr Steven Schapera
Mr Jeffrey Edwards
Dr Chris Quirk
Mr Tony Varano

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011

www.obj.com.au

ABN: 72 056 482 636

For more information:

Matthew Wright
matt@nwrcommunications.com.au
Phone: +61 451 896 420